Fractional exhaled nitric oxide in respiratory diseases

Read full text Summarise with VIRAT
Authors: Chong Zhou, Xiaoqi Li, Menglan Hao, Shuqing Chang, Jinjing Xia
Cited by: 0
References: 95

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Fractional exhaled nitric oxide (FeNO) is a simple, sensitive and non-invasive marker that can monitor eosinophilic airway inflammation. Its levels are influenced by height, weight, gender, ethnicity and smoking status. FeNO was first introduced as a biomarker to assist in asthma detection, and now plays an important auxiliary role in its diagnosis, management, and prognosis evaluation, including treatment guidance and drug efficacy assessment. With continuous exploration, exhaled nitric oxide has demonstrated utility in a variety of respiratory diseases, including chronic obstructive pulmonary disease, chronic cough and interstitial lung disease. It can also serve as a biomarker after lung surgery to indicate the risk of postoperative complications and impaired lung function. This article summarizes the clinical value of exhaled nitric oxide in common pulmonary diseases, aiming to provide a reference for its clinical application.

Fields of Study & Subjects

Asthma and respiratory diseases Chronic Obstructive Pulmonary Disease (COPD) Research Sinusitis and nasal conditions

Publication details

Journal / source
Perioperative Precision Medicine
Volume
4
Issue
1
Pages
44–56
Publication date
31 March 2026
Language
EN